BATON ROUGE, La., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of America’s leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Oppenheimer Healthcare Conference in New York, NY on Wednesday, December 9, 2015.
The presentation will begin at 1:00 p.m. Eastern. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com.
About Amedisys:
Amedisys, Inc. (Nasdaq:AMED) is a leading health care at home company delivering personalized home health and hospice care to approximately 360,000 patients each year. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. The Company's state-of-the-art advanced chronic care management programs and leading-edge technology enables it to deliver quality care based upon the latest evidence-based best practices. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry's first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient's home health plan of care. For more information about the Company, please visit: http://www.amedisys.com.
We use our company website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding the Company is routinely posted on and accessible on the "Investor Relations" subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. We will also use our website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission ("SEC") disclosing the same information. In addition, we make available on the Investor Relations subpage of our website (under the link "SEC filings") free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct and the charters for the Audit, Compensation, Nominating and Corporate Governance, Quality of Care and Compliance and Ethics Committees of our Board are also available on the Investor Relations subpage of our website (under the link "Corporate Governance").
Contact: Amedisys, Inc. David Castille Managing Director, Finance 225.299.3665 [email protected]


Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Shell M&A Chief Exits After BP Takeover Proposal Rejected 



